Date: September 23, 2025
Event format: International workshop
Location & venue: Barcelona, Spain
Registration details
Registration is free of charge and limited places are available.
For any info please contact Alessia.addessi@medexlearning.com
Language: English
The 2025 Joint Pre-ECTRIMS Workshop is designed for neurologists with specific interest in Multiple Sclerosis.
Overview
The Pre-ECTRIMS course is an annual event aimed at providing an update on the main novelties of the year in the field of MS. The 2025 edition will particularly focus on new evidence on immunopathogenetic mechanisms, imaging, and fluid biomarkers that possibly differentiate relapsing-remitting and progressive Multiple Sclerosis. Moreover, the mechanisms of action of upcoming treatments for MS will be discussed in relation to this new evidence. The ‘controversies’ session will cover the main ‘hot topics’ that are currently debated, including MS prodromes, progression independent from relapses (PIRA) as a new clinical outcome, the impact of machine learning on the improvement of MS prediction, and new evidence on late onset MS (LOMS). Since 2020, Med-Ex Learning has been providing this course in collaboration with the European Charcot Foundation, and we plan to continue this tradition in 2025 and in the future.
Learning objectives
- Describing the role of new immunological players in MS development and the mechanism of action of new immunomodulating drugs
- Addressing new treatment challenges in special populations and conditions (pregnancy, elderly…)
- Understanding how to classify disease courses and estimate prognosis in relation to new biomarkers of disease progression
Accreditation
This educational activity will be submitted to the EACCME for CME accreditation.
Preliminary Programme
Welcome & Opening
10.00 H.P. Hartung (Germany) and X. Montalban (Spain)
Session 1: Relapsing remitting and progressive MS – One or Two Diseases?
Chair: X. Montalban (Spain)
10.15 L1 – What we know about mechanistic aspects
T. Kuhlmann, Germany
10.45 L2 – Imaging biomarkers
A. Rovira, Spain
11.15 L3 – Body fluid biomarkers
J. Kuhle, Switzerland
11.35 Coffee break
11.55 L4 – New Diagnostic criteria and revision of the classification of courses
X. Montalban, Spain
12.15 L5 – Optimization of treatments
H.P. Hartung, Germany
12.35 L6 – Future treatment target and perspectives
A. Bar Or, US
12.55 Q&A
13.10 Lunch
Session 2: Controversies in MS
Chair: X. Montalban, Spain
14.10 L7 – MS prodromes: friend or foe?
R. Palladino, Italy
14.30 L8 – PIRA: chronic inflammation or neurodegeneration?
L. Kappos, Switzerland and C. Tur, Spain
14.50 L9 – Predicting disability: what’s the role of artificial intelligence?
C. Granziera, Switzerland
15.10 L10 – Late onset MS: a new clinical entity?
M. Tintorè, Spain
15.30 L11 – Treatment de-escalation: who, when, why?
H.P. Hartung, Germany
15.50 Q&A
16.10 Wrap up
16.30 End of the day
Acknowledgements
This educational activity is made possible thanks to independent educational grants by
Chair
Hans Peter Hartung
Center for Neuropsychiatry
Department of Neurology Heinrich-Heine-University Dusseldorf
Dusseldorf, Germany
Xavier Montalban
Neurology Department
Multiple Sclerosis Centre of Catalonia (Cemcat) and
Vall d’Hebron Barcelona Hospital Campus Barcelona, Spain